Developments Inventiva odiparcil gets FDA fast track designation for mucopolysaccharidosis Inventiva’s (PSE:IVA; NASDAQ:IVA) odiparcil received FDA fast track designation for the treatment of mucopolysaccharidosis (MPS) Type VI, a rare progressive genetic disorder. MPS is caused by deficient versions of the... October 20, 2020